Back to top
more

Sarepta Therapeutics (SRPT)

(Delayed Data from NSDQ)

$17.53 USD

17.53
5,608,806

+0.57 (3.36%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $17.55 +0.02 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (153 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

SRPT Stock Down After EMA Places Clinical Hold on DMD Gene Therapy

by Zacks Equity Research

The EMA pauses all clinical studies of Sarepta and Roche's Elevidys following the reported death of a treated patient

Sundeep Ganoria headshot

Biotech Stocks Fall After Top FDA Official Quits Over Clash With RFK Jr.

by Sundeep Ganoria

The decline in biotech stocks comes after FDA official Peter Marks' resignation, citing irreconcilable differences with the new HHS Secretary.

Zacks Equity Research

Sarepta Therapeutics (SRPT) Down 30.3% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Sundeep Ganoria headshot

How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion

by Sundeep Ganoria

We advise investors with a long-term horizon to remain invested in Sarepta stock, given its encouraging commercial portfolio and robust pipeline potential.

Zacks Equity Research

The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics

by Zacks Equity Research

Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics are included in this Analyst Blog.

Zacks Equity Research

Biotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & More

by Zacks Equity Research

SRPT and INCY are in the spotlight this week following a report of an adverse event and study data, respectively.

Zacks Equity Research

Strength Seen in Sarepta Therapeutics (SRPT): Can Its 8.7% Jump Turn into More Strength?

by Zacks Equity Research

Sarepta Therapeutics (SRPT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks Equity Research

SRPT Nosedives 27% on Patient Death Following DMD Therapy Infusion

by Zacks Equity Research

Despite the reported death, Sarepta maintains that its gene therapy has a favorable 'benefit-risk profile.'

Zacks Equity Research

Company News for Mar 19, 2025

by Zacks Equity Research

Companies In The Article Are:SRPT, IHS, BTU, MRP

Zacks Equity Research

SLDB Stock Rallies 60% in a Month: Here's What You Should Know

by Zacks Equity Research

Solid Biosciences stock soars 60% in a month after the company announced positive initial data from its phase I/II DMD study of SGT-003.